Real-world observational changes in biomarkers and safety profile of finerenone in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis

Background Chronic kidney disease (CKD) is a major global public health challenge. Overactivation of the aldosterone-mineralocorticoid receptor axis plays a key role in renal injury. How finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, changes albuminuria, kidney function and serum potassium in non-diabetic CKD remains unclear. Methods We searched Chinese and English databases and included observational studies investigating finerenone in non-diabetic CKD. A random-effects model was used for the meta-analysis to evaluate urinary albumin-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), serum potassium levels, and adverse events. Results Ten studies involving 326 patients were included. UACR decreased from baseline after finerenone initiation at 1, 3, and 6 months (mean change from baseline: -62.96 mg/g, 95%CI: -115.08, -10.85, P = 0.02; -319.76 mg/g, 95%CI: -627.53, -12.00, P = 0.04; and − 322.41 mg/g, 95%CI: -539.36, -105.47, P = 0.004, respectively). eGFR decreased significantly at 3 months (mean change: -5.81 mL/min/1.73 m², P < 0.001) and stabilized at 6 months. Serum potassium levels did not change significantly at any time point, and no reported episodes of hyperkalemia requiring hospitalization were identified; however, the small sample size limits detection of rare adverse events. Statistical heterogeneity was low to moderate for UACR and eGFR (I² 0%–44%). Conclusions This meta-analysis of real-world observational evidence suggests that finerenone initiation is associated with reductions in albuminuria in the non-diabetic CKD subtypes studied. These findings describe the early trajectories of albuminuria, kidney function and serum potassium after finerenone initiation in routine practice, and should be read alongside, not as a substitute for, the randomised evidence from the FIND-CKD trial.

Authors

Institutions

Publication Details

Journal
BMC Nephrology
Published
2026-11-18
DOI
https://doi.org/10.1186/s12882-026-05504-w
Primary Topic
Hormonal Regulation and Hypertension
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world observational changes in biomarkers and safety profile of finerenone in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis

Peiyi Ye, Zhe Zhang, Yaozhong Kong, Xiaoyi Liu et al.
2 links
BMC Nephrology
Hormonal Regulation and Hypertension
article

Real-world observational changes in biomarkers and safety profile of finerenone in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis

Peiyi Ye, Zhe Zhang, Yaozhong Kong, Xiaoyi Liu, Chao Xie
article en

Abstract

Background Chronic kidney disease (CKD) is a major global public health challenge. Overactivation of the aldosterone-mineralocorticoid receptor axis plays a key role in renal injury. How finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, changes albuminuria, kidney function and serum potassium in non-diabetic CKD remains unclear. Methods We searched Chinese and English databases and included observational studies investigating finerenone in non-diabetic CKD. A random-effects model was used for the meta-analysis to evaluate urinary albumin-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), serum potassium levels, and adverse events. Results Ten studies involving 326 patients were included. UACR decreased from baseline after finerenone initiation at 1, 3, and 6 months (mean change from baseline: -62.96 mg/g, 95%CI: -115.08, -10.85, P = 0.02; -319.76 mg/g, 95%CI: -627.53, -12.00, P = 0.04; and − 322.41 mg/g, 95%CI: -539.36, -105.47, P = 0.004, respectively). eGFR decreased significantly at 3 months (mean change: -5.81 mL/min/1.73 m², P < 0.001) and stabilized at 6 months. Serum potassium levels did not change significantly at any time point, and no reported episodes of hyperkalemia requiring hospitalization were identified; however, the small sample size limits detection of rare adverse events. Statistical heterogeneity was low to moderate for UACR and eGFR (I² 0%–44%). Conclusions This meta-analysis of real-world observational evidence suggests that finerenone initiation is associated with reductions in albuminuria in the non-diabetic CKD subtypes studied. These findings describe the early trajectories of albuminuria, kidney function and serum potassium after finerenone initiation in routine practice, and should be read alongside, not as a substitute for, the randomised evidence from the FIND-CKD trial.

BMC Nephrology
Southern University of Science and Technology (CN), First People's Hospital of Foshan (CN)
Good health and well-being
Hormonal Regulation and Hypertension
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon